@article{80b6ffefbdf640118d8c8becd544431a,
title = "Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma",
abstract = "Background: Exposures to DNA-damaging drugs and ionizing radiations increase risks of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Methods: 9028 recipients of hematopoietic cell autotransplants (1995–2010) for Hodgkin lymphoma (HL; n = 916), non-Hodgkin lymphoma (NHL; n = 3546) and plasma cell myeloma (PCM; n = 4566), reported to the CIBMTR, were analyzed for risk of subsequent AML or MDS. Results: 335 MDS/AML cases were diagnosed posttransplant (3.7%). Variables associated with an increased risk for AML or MDS in multivariate analyses were: (1) conditioning with total body radiation versus chemotherapy alone for HL (HR = 4.0; 95% confidence interval [1.4, 11.6]) and NHL (HR = 2.5 [1.1, 2.5]); (2) ≥3 versus 1 line of chemotherapy for NHL (HR = 1.9 [1.3, 2.8]); and (3) subjects with NHL transplanted in 2005–2010 versus 1995–1999 (HR = 2.1 [1.5, 3.1]). Using Surveillance, Epidemiology and End Results (SEER) data, we found risks for AML/MDS in HL, NHL and PCM to be 5–10 times the background rate. In contrast, relative risks were 10–50 for AML and approximately 100 for MDS in the autotransplant cohort. Conclusions: There are substantial risks of AML and MDS after autotransplants for HL, NHL and PCM.",
keywords = "AML, Autotransplant, CIBMTR, MDS, New cancers, SEER, Therapy-related",
author = "Tomas Radivoyevitch and Dean, {Robert M.} and Shaw, {Bronwen E.} and Ruta Brazauskas and Tecca, {Heather R.} and Molenaar, {Remco J.} and Minoo Battiwalla and Savani, {Bipin N.} and Flowers, {Mary E.D.} and Cooke, {Kenneth R.} and Hamilton, {Betty K.} and Matt Kalaycio and Maciejewski, {Jaroslaw P.} and Ibrahim Ahmed and G{\"o}rg{\"u}n Akpek and Ashish Bajel and David Buchbinder and Cahn, {Jean Yves} and Anita D'Souza and Andrew Daly and Zachariah DeFilipp and Siddhartha Ganguly and Mehdi Hamadani and Hayashi, {Robert J.} and Peiman Hematti and Yoshihiro Inamoto and Nandita Khera and Tamila Kindwall-Keller and Heather Landau and Hillard Lazarus and Majhail, {Navneet S.} and Marks, {David I.} and Olsson, {Richard F.} and Sachiko Seo and Amir Steinberg and William, {Basem M.} and Baldeep Wirk and Yared, {Jean A.} and Mahmoud Aljurf and Abidi, {Muneer H.} and Heather Allewelt and Amer Beitinjaneh and Rachel Cook and Cornell, {Robert F.} and Fay, {Joseph W.} and Gregory Hale and Chakrabarty, {Jennifer Holter} and Sonata Jodele and Kasow, {Kimberly A.} and Anuj Mahindra and Malone, {Adriana K.} and Uday Popat and Rizzo, {J. Douglas} and Schouten, {Harry C.} and Warwick, {Anne B.} and Wood, {William A.} and Sekeres, {Mikkael A.} and Litzow, {Mark R.} and Gale, {Robert P.} and Hashmi, {Shahrukh K.}",
note = "Funding Information: The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 4U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-17-1–2388 and N0014-17-1–2850 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, Inc.; *Amgen, Inc.; *Amneal Biosciences; *Angiocrine Bioscience, Inc.; Anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; Atara Biotherapeutics, Inc.; Be the Match Foundation; *bluebird bio, Inc.; *Bristol Myers Squibb Oncology; *Celgene Corporation; Cerus Corporation; *Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Gilead Sciences, Inc.; HistoGenetics, Inc.; Immucor; *Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Juno Therapeutics; Karyopharm Therapeutics, Inc.; Kite Pharma, Inc.; Medac, GmbH; MedImmune; The Medical College of Wisconsin; *Mediware; *Merck & Co, Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; *Neovii Biotech NA, Inc.; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co, Ltd. – Japan; PCORI; *Pfizer, Inc; *Pharmacyclics, LLC; PIRCHE AG; *Sanofi Genzyme; *Seattle Genetics; Shire; Spectrum Pharmaceuticals, Inc.; St. Baldrick's Foundation; *Sunesis Pharmaceuticals, Inc.; Swedish Orphan Biovitrum, Inc.; Takeda Oncology; Telomere Diagnostics, Inc.; and University of Minnesota. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. TR is supported by the National Aeronautics and Space Administration (NNJ13ZSA001N). RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme. *Corporate Members Funding Information: The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the National Cancer Institute (NCI) , the National Heart , Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID) ; a Grant/Cooperative Agreement 4U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-17-1–2388 and N0014-17-1–2850 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, Inc.; *Amgen, Inc.; *Amneal Biosciences; *Angiocrine Bioscience, Inc.; Anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; Atara Biotherapeutics, Inc.; Be the Match Foundation; *bluebird bio, Inc.; *Bristol Myers Squibb Oncology; *Celgene Corporation; Cerus Corporation; *Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Gilead Sciences, Inc.; HistoGenetics, Inc.; Immucor; *Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Juno Therapeutics; Karyopharm Therapeutics, Inc.; Kite Pharma, Inc.; Medac, GmbH; MedImmune; The Medical College of Wisconsin; *Mediware; *Merck & Co, Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; *Neovii Biotech NA, Inc.; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co, Ltd. – Japan; PCORI; *Pfizer, Inc; *Pharmacyclics, LLC; PIRCHE AG; *Sanofi Genzyme; *Seattle Genetics; Shire; Spectrum Pharmaceuticals, Inc.; St. Baldrick{\textquoteright}s Foundation; *Sunesis Pharmaceuticals, Inc.; Swedish Orphan Biovitrum, Inc.; Takeda Oncology; Telomere Diagnostics, Inc.; and University of Minnesota. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. TR is supported by the National Aeronautics and Space Administration (NNJ13ZSA001N). RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme. *Corporate Members Publisher Copyright: {\textcopyright} 2018",
year = "2018",
month = nov,
doi = "10.1016/j.leukres.2018.07.016",
language = "English (US)",
volume = "74",
pages = "130--136",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
}